a satellite virusoid employing HBV envelope proteins for the entry into hepatocytes. To date, no effective therapy for HDV infection exists. Thus, entry inhibition may represent the first ...
“Even with long-term antiviral treatment, basal levels of the HBV oncogenic X protein (HBx) remain in hepatocytes to promote genomic instability and disease progression.” The hepatitis B ...
Inside the hepatocytes, HBV produces a surplus of viral antigens, including hepatitis B e antigen (HBeAg) and hepatitis B s antigen (HBsAg), which is HBV’s envelope protein. In addition to the ...
Researchers at Oregon Health & Science University have developed the first transgenic nonhuman primate model—genetically modified to carry a human gene—for studying hepatitis B virus. The breakthrough ...
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo g ...
Hosted on MSN11mon
Study describes structure of antiviral drug bulevirtide bound to hepatitis B and D virus receptor protein NTCPwhich holds promise for developing additional therapeutic interventions against HBV/HDV, preventing viral entry into hepatocytes, and thus reducing HBV/HDV-related liver damage. Liu H. and ...
Researchers say if their results are confirmed through further study they are optimistic the approach could be used to treat chronic infections for the first time.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback